Imagine a giant shared library where instead of books, scientists share chemical compounds to see which ones can stop a disease. This project is upgrading that library with better search tools, smarter AI, and more realistic 'test tubes' that mimic human cells. It makes it much faster and cheaper for researchers to find the right chemical key to unlock a cure.
Early drug discovery is expensive and risky due to the high cost of screening compounds and the lack of realistic cellular models. Companies often lack the specialized equipment for chemoproteomics or spatial omics.
An expanded suite of screening services including AI-driven mode-of-action prediction, spatial MS-based omics, and validated CRISPR-Cas9 genetic screening models.
If you are a drug discovery biotech dealing with high costs of early-stage screening — this project developed a distributed infrastructure of 33 partner sites that provides open access to compound screening and AI-driven prediction. This allows you to validate targets without building your own multi-million euro lab.
If you are a specialized modality developer dealing with the complexity of PROTACs or covalent probes — this project developed validated services for new chemical modalities. This helps you move from a chemical concept to a validated lead more reliably.
If you are an AI-driven drug design firm dealing with poor quality training data — this project developed common operational and data standards to increase FAIRness and reproducibility. This provides higher quality data for training mode-of-action prediction models.
Based on available project data, EU-OPENSCREEN is an open-access initiative, but specific pricing for industry users is not listed in the provided text.
Yes, the infrastructure is distributed across 33 partner sites in 10 countries, providing high-throughput compound screening capabilities.
The project utilizes Material Transfer Agreements, as evidenced by the 16 agreements already established to share compounds.
It integrates via a central compound management facility and the European Chemical Biology Database (ECBD) to provide interoperable data.
The project runs from 2024-03-01 to 2027-02-28, with some services like chemoproteomics already launched during the first reporting period.
The consortium is heavily weighted toward public research, consisting of 12 universities and 13 research organizations across 10 countries. There are currently 0 industry partners or SMEs involved, indicating that the project is focused on building the foundational infrastructure and open-access tools that industry can later leverage for pre-competitive research.
Contact EU-OPENSCREEN ERIC
Contact us to identify which of the 33 partner sites best fits your chemical modality needs.
